This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
Why HealthEquity (HQY) Isn't Done Growing Earnings Yet
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider HealthEquity (HQY).
ESRX vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESRX vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
HealthEquity's (HQY) impressive results in Q3 can be attributed to solid growth in HSA Members. Its bullish guidance for fiscal 2019 further raises investors' optimism on the stock.
HealthEquity (HQY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 12.00% and 1.06%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will HSA Member Growth Aid HealthEquity's (HQY) Q3 Earnings?
by Zacks Equity Research
HealthEquity's (HQY) top line is likely to be driven by solid Health Savings Accounts (HSA) member growth in the fiscal third quarter. However, cutthroat competition in the niche space is concerning.
ESRX or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESRX vs. HQY: Which Stock Is the Better Value Option?
Is HealthEquity (HQY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
ESRX or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESRX vs. HQY: Which Stock Is the Better Value Option?
Near-Term Outlook for Medical Services Industry Looks Bright
by Urmimala Biswas
Growing importance of efficient healthcare management is positioning the providers of medical services well to benefit.
Here's Why You Should Buy HealthEquity (HQY) Stock Right Now
by Zacks Equity Research
Strong presence in the HSA space and a solid guidance for fiscal 2019 make HealthEquity (HQY) a promising investment pick.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
HealthEquity (HQY) Down 3.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc Leads Telehealth Thanks to its Virtual Care Solution
by Zacks Equity Research
Teladoc's (TDOC) vast product portfolio, client base, tie-ups and acquisitions make it a leader in the telehealth industry.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
Here's Why Momentum Investors Will Love HealthEquity (HQY)
by Zacks Equity Research
Does HealthEquity (HQY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Looking for a Growth Stock? Why It is Time to Focus on HealthEquity (HQY)
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider HealthEquity (HQY).
HealthEquity (HQY) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Strong HSA Member growth boosts HealthEquity's (HQY) results in Q2. A strong guidance raises investors??? optimism.
Can HSA Member Growth Drive HealthEquity's (HQY) Q2 Earnings?
by Zacks Equity Research
HealthEquity (HQY) is likely to register solid HSA member growth in the quarter to be reported.
HealthEquity (HQY) Q2 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SYNH or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SYNH vs. HQY: Which Stock Is the Better Value Option?
CIVI or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CIVI vs. HQY: Which Stock Is the Better Value Option?
SYNH vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SYNH vs. HQY: Which Stock Is the Better Value Option?
NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session
by Zacks Equity Research
NovoCure (NVCR) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.